

**ATT: No**

Either:

1. **this complaint was not filed with exhibits or attachments, or**
2. **all exhibits/attachments filed with complaint are attached to this copy**

**Case Number:**

**Case File Date:**

**NOS:**

MARTIN SCHMIDT, ESQ. (SBN 171673)  
SCHMIDT NATIONAL LAW GROUP  
9191 Towne Centre Drive, Suite 510  
San Diego, CA 92122  
Telephone: (800) 631-5656  
Facsimile: (800) 631-1777  
Email: [mschmidt@nationalinjuryadvocates.com](mailto:mschmidt@nationalinjuryadvocates.com)

AND

Scott P. Schlesinger (*pro hac vice anticipated*)  
Jonathan R. Gdanski (*pro hac vice anticipated*)  
Jeffrey L. Haberman (*pro hac vice anticipated*)  
SCHLESINGER LAW OFFICES, P.A.  
1212 SE Third Avenue  
Ft. Lauderdale, FL 3316  
Tel: 954-467-8800  
Email: [scott@schlesingerlaw.com](mailto:scott@schlesingerlaw.com)  
[jgdanski@schlesingerlaw.com](mailto:jgdanski@schlesingerlaw.com)  
[haberman@schlesingerlaw.com](mailto:haberman@schlesingerlaw.com)

Counsel for Plaintiff

IN THE SUPERIOR COURT OF THE STATE OF CALIFORNIA  
FOR THE COUNTY OF SAN FRANCISCO  
CIVIL-UNLIMITED JURISDICTION

CODY BOYENS, an individual

Plaintiffs,

vs.

JUUL LABS, INC., ALTRIA GROUP,  
INC., PHILIP MORRIS USA, INC., ADAM  
BOWEN and JAMES MONSEES

Defendants.

CASE NO. CGC-19-577875

COMPLAINT AND DEMAND FOR JURY  
TRIAL

(1) CIVIL CONSPIRACY;  
(2) FRAUD;  
(3) STRICT PRODUCT LIABILITY-  
FAILURE TO WARN;  
(4) STRICT PRODUCT  
LIABILITY-DESIGN DEFECT  
(5) NEGLIGENCE;  
(6) UNJUST ENRICHMENT;  
(7) VIOLATION OF CAL. BUSINESS  
CODE § 17200  
(8) VIOLATION OF CCP §1770  
(9) PRELIMINARY AND PERMANENT  
INJUNCTION

FILED  
Superior Court of California  
County of San Francisco

JUL 23 2019

CLERK OF THE COURT

BY: [Signature]

Deputy Clerk

BOWMAN

BY FAX

1  
2  
3 **COMPLAINT AND DEMAND FOR JURY TRIAL**

4 1. Plaintiff, Cody Boyens, through his undersigned counsel, brings this action against  
5 Defendants JUUL Labs, Inc., Altria Group, Inc., and Philip Morris USA, Inc., Adam Bowen, and  
6 James Monsees and alleges as follows:

7 **INTRODUCTION**

8 2. Plaintiff is only 19 years old yet he is addicted to JUUL, an e-cigarette. Health  
9 authorities consider youth e-cigarette use an epidemic. Defendants are to blame. Mimicking Big  
10 Tobacco's past marketing practices, Defendants prey on youth to recruit replacement smokers for  
11 financial gain. Tobacco giant Altria recently acquired a 35% stake in JUUL, the country's lead e-  
12 cigarette seller. Altria also owns Philip Morris, which sells Marlboro, the country's most popular  
13 cigarette. Now that JUUL has Altria's infrastructure, progress in nicotine cessation stands to erode.  
14 Defendants use the very fraudulent and deceptive youth marketing business practices adjudged to  
15 violate federal racketeering laws. They exploit themes that resonate with teenagers while falsely  
16 denying doing so:  
17  
18  
19  
20



1 Plaintiff brings this lawsuit to redress the harm already sustained and to prevent future harm to others.

2  
3 **PARTIES, JURISDICTION, AND VENUE**

4 3. Plaintiff, Cody Boyens resides in Riverside County, California, and is a citizen of the  
5 State of California. Plaintiff who is 19 years old, began using and purchasing JUUL vaping products  
6 when he was 17. Plaintiff did not know how much nicotine JUUL contained or that JUUL was  
7 specifically developed to create and sustain a nicotine addiction when he began using it. Plaintiff was  
8 attracted to and used JUUL's Mango and Mint flavors. Plaintiff is addicted to the nicotine contained  
9 in JUUL. Plaintiff suffers from nicotine addiction. Plaintiff was directly and proximately harmed by  
10 Defendants' unlawful conduct as alleged in this complaint. Such harm includes personal injury,  
11 exposure to significant toxic substances, which may cause or contribute to causing disease; nicotine  
12 addiction; economic harm in that he would not have purchased JUUL if he knew the facts  
13

14 4. Plaintiff is concerned for his health and his future health because of the known  
15 complications associated with nicotine usage. Plaintiff reasonably fears that the Defendants listed  
16 below are working in concert to market and advertise JUUL to youth and teenagers and that  
17 Defendants' association and marketing efforts increase the likelihood that other youth will begin  
18 using e-cigarettes and become addicted. Unless these Defendants are enjoined from their unlawful  
19 acts as described below, the harms will continue.  
20

21 5. Defendant JUUL Labs, Inc. ("JUUL"), is a Delaware corporation, having its principal  
22 place of business in San Francisco, California. JUUL originally operated under the name PAX Labs,  
23 Inc. In 2017, it was renamed JUUL Labs, Inc. JUUL manufactures, designs, sells, markets, promotes  
24 and distributes JUUL e-cigarettes.  
25

26 6. Defendant, Altria Group, Inc. ("Altria"), is a Virginia corporation, having its principal  
27 place of business in Richmond, Virginia.  
28

1           7. Defendant, Philip Morris USA, Inc. (Philip Morris), is a wholly-owned subsidiary of  
2 Altria. Philip Morris is a Virginia corporation, having its principal place of business in Richmond,  
3 Virginia. Philip Morris is engaged in the manufacture and sale of cigarettes in the United States. Philip  
4 Morris is the largest cigarette company in the United States. Marlboro, the principal cigarette brand of  
5 Philip Morris, has been the largest-selling cigarette brand in the United States for over 40 years.

6           8. Altria and Philip Morris are referred to collectively as the Altria Defendants. Altria  
7 acquired 35% ownership in JUUL to, among other things, sell, promote, market, and distribute JUUL  
8 e-cigarettes. Pursuant to a services agreement, JUUL will have access to Altria Defendants' industry  
9 infrastructure.  
10

11           9. Defendant Adam Bowen resides in San Mateo, California. Adam Bowen co-founded  
12 PAX labs, Inc. in 2007, which rebranded to JUUL Labs, Inc. in 2017. Adam Bowen has been  
13 instrumental in the creation of JUUL, including its invention, nicotine manipulation and delivery,  
14 marketing, and advertising. Mr. Bowen promotes the sale of JUUL and has given industry  
15 presentations about the e-cigarette. Mr. Bowen's actions mislead youth and JUUL users into thinking  
16 the device is not harmful or as addictive as it is.  
17

18           10. Defendant James Monsees resides in San Francisco, California. James Monsees  
19 founded PAX labs, Inc. in 2007, which rebranded to JUUL Labs, Inc. in 2017. Mr. Monsees has been  
20 instrumental in the creation of JUUL, including its invention, nicotine manipulation and delivery,  
21 marketing, and advertising. Mr. Monsees promotes the sale of JUUL and has given industry  
22 presentations about the e-cigarette, including on the perceived therapeutic effects of JUUL, though  
23 without scientific substantiation. Mr. Monsees' actions mislead youth and other JUUL users into  
24 thinking the device is not harmful or as addictive as it is  
25

26           11. The Court has subject matter jurisdiction over this action because it exceeds twenty-  
27 five thousand dollars (\$25,000.00), exclusive of costs and fees.  
28

1           12.     The Court has personal jurisdiction over all Defendants because they do business in  
2 California and have sufficient minimum contacts with San Francisco County, California. Additionally,  
3 Defendant JUUL has its principal place of business in San Francisco County. Defendants intentionally  
4 avail themselves of the markets in this State through the promotion, marketing, distribution or sale of  
5 the products at issue in this lawsuit to render the exercise of jurisdiction by this Court permissible under  
6 California law and the U.S. Constitution.

7  
8           13.     Venue is proper in this Court pursuant to Cal. Civ. Proc. Code § 395 in “the county  
9 where the injury occurs.” Here, the injury occurred in San Francisco County, California and Defendants  
10 are subject to the Court’s personal jurisdiction with respect to this action. CAL. CIV. PROC. CODE § 395  
11 (West 2019).

12  
13                               **GENERAL FACTUAL ALLEGATIONS**

14           **A. The E-Cigarette Epidemic**

15           14.     According to the CDC, about 4.9 million middle and high school students were current  
16 users of a tobacco product in 2018, meaning that they used such products within the past 30 days.  
17 This represents an increase of 1.3 million users just since 2017.<sup>1</sup>

18  
19           15.     A surge in e-cigarette use explains this dramatic increase: There were 1.5 million  
20 more youth e-cigarette users in 2018 than 2017, accounting for more than the full increase in youth  
21 tobacco usage and erasing past progress in reducing youth tobacco product use. E-cigarette use  
22 among U.S. high school students increased more than 900% from 2011 to 2015. Frequent use of e-  
23 cigarettes increased from 20 percent in 2017 to 28 percent in 2018. E-cigarette use in general  
24 increased 78 percent among high school students and 48 percent among middle school students from  
25 2017 to 2018. As CDC Director Dr. Robert R. Redfield explains: “The skyrocketing growth of young  
26  
27

28  

---

<sup>1</sup> See <https://www.cdc.gov/media/releases/2019/p0211-youth-tobacco-use-increased.html>.

1 people's e-cigarette use over the past year threatens to erase progress made reducing tobacco use. It's  
2 putting a new generation at risk for nicotine addiction."

3 16. Many youth tobacco product users are also using multiple tobacco products: a  
4 combination of e-cigarettes and conventional cigarettes.

5 17. The FDA characterizes teen vaping as an epidemic. And with good reason: Smoking  
6 is the leading cause of preventable death. Cigarette smoking causes about one in every five deaths in  
7 the United States each year. This amounts to around 480,000 deaths annually. If smoking continues  
8 at the current rate among U.S. youth, 5.6 million of today's Americans younger than 18 years of age  
9 are expected to die prematurely from a smoking-related illness. This represents about one in every 13  
10 Americans aged 17 years or younger who are alive today.

11 18. A study done by the American Journal of Medicine found that among young adults  
12 who did not smoke cigarettes, those who used e-cigarettes were more than four times as likely than  
13 non-vapers to start smoking traditional cigarettes within 18 months.<sup>2</sup>

14 19. JUUL e-cigarettes and JUULpods deliver dangerous toxins and carcinogens to users,  
15 especially teenage users. Nicotine itself is a carcinogen, as well as a toxic chemical associated with  
16 cardiovascular, reproductive, and immunosuppressive problems.

17 20. Nicotine adversely affects the heart, eyes, reproductive system, lungs, and kidneys.  
18 Exposure to nicotine from sources such as nicotine gum still produces an increased risk of Coronary  
19 Vascular Disease by producing acute myocardial ischemia, as well as an increased risk of peripheral  
20 arterial disorders. Moreover, because vaping introduces foreign substances into the lungs, prolonged  
21 use of vaping products is believed to produce chronic obstructive pulmonary disease, just like  
22 traditional cigarette smoke. Vaping also triggers immune responses associated with inflammatory  
23 lung diseases.

24  
25  
26  
27  
28 <sup>2</sup> Primack, Brian A. MD, PhD. "Initiation of Traditional Cigarette Smoking after Electronic Cigarette  
Use Among Tobacco-Naïve US Young Adults." The Am. J. of Medicine. November 2017.

1           21.     According to the National Institutes of Health, the “amount and speed of nicotine  
2 delivery . . . plays a critical role in the potential for abuse of tobacco products.”<sup>3</sup> Big Tobacco has  
3 long known that nicotine addiction is the reason for tobacco product usage.

4           **B. The JUUL E-Cigarette**

5           22.     Since its launch in 2015, JUUL has become the dominant e-cigarette manufacturer in  
6 the United States. Its revenues grew by 700% in 2017. According to a recent Wells-Fargo report,  
7 JUUL owns three-quarters of the e-cigarette market.<sup>4</sup>

8           23.     JUUL is a novel cartridge-based e-cigarette design. The cartridges are called pods or  
9 JUULpods. JUUL devices heat up a cartridge containing oils to create vapor, which quickly dissolves  
10 into the air. JUUL describes the e-cigarettes as an “easy to use vaporizer.”

11           24.     The JUUL e-cigarette is a sleek, high-tech design. It looks like a USB flash drive, and  
12 it can charge in a computer. It is about the size and shape of a pack of chewing gum; it is small  
13 enough to fit in a closed hand. JUUL is easy to conceal from parents and teachers. The odor emitted  
14 from JUUL is a reduced aerosol – unlike the distinct smell of conventional cigarettes.  
15

16           25.     The thin, rectangular JUUL e-cigarette device consists of an aluminum shell, a battery,  
17 a magnet (for the USB-charger), a circuit board, an LED light, and a pressure sensor. Each JUULpod  
18 is a plastic enclosure containing 0.7 milliliters of JUUL’s patented nicotine liquid and a coil heater.  
19 When a sensor in the JUUL e-cigarette detects the movement of air caused by suction on the  
20 JUULpod, the battery in the JUUL device activates the heating element, which in turn converts the  
21 nicotine solution in the JUULpod into a vapor consisting principally of nicotine, benzoic acid,  
22 glycerin, and propylene glycol. A light embedded in the JUUL device serves as a battery level  
23 indicator and lights up in a “party mode” display of rainbow of colors when the device is waved  
24 around.  
25  
26

27  
28 <sup>3</sup> See <https://www.ncbi.nlm.nih.gov/books/NBK53018/#ch4.s92>

<sup>4</sup> <https://www.durbin.senate.gov/imo/media/doc/FINAL%20JUUL%20Letter%204.8.19.pdf>



1           26.     The physical design of the JUUL device (including its circuit board) and JUULpod  
2 determines the amount of aerosolized nicotine the JUUL emits. By altering the temperature, maximum  
3 puff duration, or airflow, among other things, JUUL precisely controls amount of nicotine vapor  
4 delivered. Studies show that there is a “decrease in the perceived harshness of the aerosol to the user  
5 and thus a greater abuse liability.” See Duell, James F. Pankow, and David H. Peyton, *Free-Base*  
6 *Nicotine Determination in Electronic Cigarette Liquids by 1H NMR Spectroscopy*, 31 Chem. Res.  
7 Toxicol. 431, 431 (2018) (“the Duell study”).  
8

9           27.     JUUL designed its products to replicate the “feel” of traditional cigarettes, and this  
10 design makes it easier for e-cigarette users to transition to conventional cigarettes because of the  
11 similarity. Indeed, JUUL says its devices “mirror the simplicity that smokers are accustomed to.”<sup>5</sup>  
12

13           28.     The JUUL e-cigarette is defectively designed and therefore unreasonably dangerous.  
14 JUUL is designed to create and sustain a nicotine addiction. JUUL appears to deliver nicotine more  
15 effectively and at higher doses than other e-cigarettes, increasing users’ risk of addiction. JUUL’s  
16 patented JUULSalts approach to nicotine delivery is due to compounds called nicotine salts, which  
17 develop in heat-dried tobacco leaves much like most cigarettes. According to the company website,  
18 freebase nicotine is mixed with benzoic acid to make the e-liquid, which has a chemical reaction to  
19 produce the nicotine salts. JUULPod e-liquid cartridges contain up to twice the amount of nicotine as  
20 a pack of cigarettes and are easier to inhale. This design method increases JUUL’s inhale-ability. The  
21 Duell study concluded that JUUL’s use of nicotine salts “may well contribute to the current use  
22 prevalence of JUUL products among youth.” *Id.* 433  
23

24           29.     Moreover, the JUUL device does not have a manual or automatic “off” switch. Neither  
25 the JUULpod nor the programming of the JUUL device’s temperature or puff duration settings limits  
26 the amount of nicotine JUUL delivers in each puff to the upper bound of a cigarette.  
27

28           <sup>5</sup> See <https://support.juul.com/home/learn/faqs/juul-device-basics> (last visited Apr. 9, 2019)

1 30. JUUL e-cigarettes and JUULpods deliver dangerous toxins and carcinogens to users,  
2 especially teenage users.

3 31. JUUL delivers doses of nicotine that are materially higher than combustible cigarettes.  
4 The United Kingdom Medicines and Healthcare Products Regulatory Agency notes, "an e-cigarette  
5 with a concentration of 20 mg/ml delivers approximately 1 milligram of nicotine in 5 minutes (the time  
6 needed to smoke a traditional cigarette, for which the maximum allowable delivery is 1 mg of  
7 nicotine).<sup>6</sup> JUUL's nicotine concentration is 59 mg/ml, which is in a salt form that increases the rate and  
8 efficiency of nicotine delivery. JUULpods therefore exceed the nicotine dose of a traditional cigarette.  
9

10 32. Comparison of available data regarding per-puff nicotine intake corroborates the  
11 other JUUL studies (mentioned above), indicating that JUUL delivers about 30% more nicotine per  
12 puff. Specifically, a recent study of JUULpods found that "[t]he nicotine levels delivered by the  
13 JUUL are similar to or even higher than those delivered by cigarettes." Reilly et al., *Free Radical,*  
14 *Carbonyl, and Nicotine Levels Produced by JUUL Electronic Cigarettes*, 3 (the "Reilly study"). The  
15 Reilly study tested JUUL's Tobacco, Crème Brulee, Fruit Punch, and Mint flavors and found that a  
16 puff of JUUL delivered  $164 \pm 41$  micrograms ( $\mu\text{g}$ ) of nicotine per puff. Reilly et al. *Free Radical*. See  
17 Appendix B, Chart 7. Reilly's findings were based on a puff volume of 75/ml. By comparison, a 2014  
18 study using larger, 100 ml puffs found that a Marlboro cigarette delivered 152—193  $\mu\text{g/puff}$ . M.J.  
19 Schroeder and A.C. Hoffman, *Electronic Cigarettes and Nicotine Clinical Pharmacology*, Tobacco  
20 Control 2014; 23:ii30-ii35. Correcting to account for the different puff sizes between the Reilly and  
21 Schroeder studies, this suggests that, at 75ml/puff, a Marlboro would deliver between 114 and 144  
22  $\mu\text{g/puff}$ . In other words, empirical data suggests that JUUL delivers up to 36% more nicotine per puff  
23 than a Marlboro.  
24  
25  
26  
27

28 <sup>6</sup> E-Cigarettes, [https://ec.europa.eu/health/sites/health/files/tobacco/docs/fs\\_ecigarettes\\_en.pdf](https://ec.europa.eu/health/sites/health/files/tobacco/docs/fs_ecigarettes_en.pdf) (last visited Apr. 9, 2019).

1           33.     Adding to the above defects, JUUL is also defective in design because it puts e-  
2 cigarette users, especially youth or young adults with developing brains, at greater risk of  
3 experiencing seizures.<sup>7</sup> JUUL's design for nicotine delivery, nicotine content, nicotine formulation  
4 and their effects on creating or sustaining nicotine addiction increases the propensity of abnormal  
5 electrical activity in the brain. JUUL is further defectively designed in that its users may unwittingly  
6 swallow the e-liquid. These defects can cause or substantially contribute to causing mild or major  
7 seizures. The FDA is currently investigating reports of youth and young adults who are experiencing  
8 seizures following the use of e-cigarettes.  
9

10           **B. JUUL Fraudulently Concealed Important Safety Information On How Addictive It's**  
11           **E-Cigarettes Are**

12           34.     JUUL has fraudulently concealed material information about the addictive nature of  
13 its e-cigarettes. Plaintiff's claims arise out of JUUL's fraudulent concealment of material facts  
14 concerning the JUUL e-cigarette and representations about the JUUL e-cigarettes' nicotine content,  
15 its addictiveness, and the physiological effects of JUUL e-cigarettes.

16           35.     At all relevant times, JUUL knew that JUUL e-cigarettes' were not safe for non-  
17 smokers, and posed a risk of aggravating nicotine addiction in those already addicted to cigarettes.  
18 JUUL was under a duty to disclose this material information based upon its exclusive knowledge of it,  
19 and its concealment of it; yet JUUL never disclosed the defect to Plaintiff or the public.  
20

21           36.     JUUL repeatedly represented that a single JUULpod contains an amount of nicotine  
22 equivalent to about a pack of cigarettes. For example, some JUUL advertisements and JUUL's  
23 website currently provides that each "JUULpod is designed to contain approximately 0.7mL with 5%  
24 nicotine by weight at time of manufacture which is approximately equivalent to 1 pack of cigarettes  
25 or 200 puffs." This falsehood is recast in JUUL advertisements, and on JUUL's website, into the  
26 claim that a JUUL delivers about as much nicotine as a cigarette.  
27

28           

---

<sup>7</sup> <https://www.fda.gov/TobaccoProducts/NewsEvents/ucm635133.htm>

1           37.     This statement is false because, as JUUL knows, it is not just the amount of nicotine,  
2 but the efficiency with which the product delivers nicotine into the bloodstream, that determines the  
3 product's narcotic effect and risk of addiction. Defendants know that benzoic acid affects pH and  
4 "absorption of nicotine across biological membranes."<sup>8</sup>

5           38.     JUUL's statement in its advertisements that each JUULpod contains about as much  
6 nicotine as a pack of cigarettes is false and likely to mislead, because the amount of nicotine  
7 contained in the JUULpod is perhaps six times less than in a pack of cigarettes, but actual amount of  
8 nicotine consumed via JUULpod is as much as twice as high as that via cigarettes.

9  
10          39.     Despite making numerous revisions to its packaging since 2015, JUUL did not add  
11 nicotine warnings until forced to do so in August of 2018.

12          40.     JUUL has not been approved as a smoking therapy nor has it been approved as a  
13 modified risk tobacco product.

14          41.     JUUL fails to inform users that its products have not been found to be safe and  
15 effective by the FDA for the purpose of smoking cessation.

16  
17           **C. JUUL Copied Big Tobacco's Youth Marketing Playbook To Addict Youth to**  
18           **Nicotine**

19          42.     JUUL adopted the same themes used by Philip Morris and other Big Tobacco  
20 companies in the cigarette industry's long-standing, extensive advertising campaign to glamorize  
21 cigarette smoking while downplaying its addictiveness and deleterious health effects.

22          43.     Statements by JUUL's founder and employees make clear JUUL's intent to develop a  
23 highly addictive product to sell to a new audience of non-smokers. James Monsees, one of JUUL's  
24 founders, described the cigarette as "the most successful consumer product of all time . . . an  
25

26  
27           <sup>8</sup> Neil L. Benowitz et al., *Nicotine Chemistry, Metabolism, Kinetics and Biomarkers*, Handbook of  
28 Experimental Pharmacology 1982: 29-60 (Oct. 13, 2010), available at: [HYPERLINK](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953858/)  
"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953858/"  
<https://www.fda.gov/TobaccoProducts/NewsEvents/ucm635133.htm>

1 amazing product.” According to Monsees, JUUL aimed to “deliver[] solutions that refresh the magic  
2 and luxury of the tobacco category.”

3 44. JUUL used the tobacco industry’s prior practices as a playbook. Monsees admitted  
4 publicly that JUUL began by looking at tobacco industry documents, including board meeting minutes.  
5 “It became a very intriguing space for us to investigate because we had so much information that you  
6 wouldn’t normally be able to get in most industries. And we were able to catch up, right, to a huge,  
7 huge industry in no time. And then we started building prototypes.”

8 45. JUUL’s research included documents about how tobacco companies had chemically  
9 manipulated nicotine content to maximize delivery: “We started looking at patent literature. We are  
10 pretty fluent in ‘Patentese.’ And we were able to deduce what had happened historically in the  
11 tobacco industry.”

12 46. JUUL also used tobacco industry advertisements—which were created to lure non-  
13 smoking youth—as a guide to JUUL’s own advertising campaigns. In a 2018 interview, “Monsees  
14 indicated that the design of JUUL’s advertising had been informed by traditional tobacco  
15 advertisements and that [the Stanford Research into Impact of Tobacco Advertising] had been quite  
16 useful to them.” Robert K. Jackler, M.D. et al, *JUUL Advertising Over Its First Three Years on the*  
17 *Market* (Jan. 21, 2019).

18 47. These copycat advertising and marketing practices include: colorful ad campaigns  
19 using eye-catching designs and youth-oriented imagery touting themes of being “cool,” “carefree,”  
20 “stylish,” “attractive,” “sexy,” “pleasureful,” “popular” and that the JUUL e-cigarettes are “great  
21 tasting,” etc. Viral marketing campaigns push JUUL products on children, teens, and young adults.  
22 For example, it is suspected that JUUL pays social media stars or social media influencers to flood  
23 social media newsfeeds with JUUL promotion – Big Tobacco did the same type of product placement  
24 to create viral campaigns of smoking. Like Big Tobacco before it, JUUL distributed free e-cigarette and  
25 packs at live social events.  
26  
27  
28

1           48.     JUUL's original marketing campaign included billboards, YouTube videos, advertising  
2 in magazines, like VICE Magazine, launch parties, and a sampling tour.

3           49.     One study of JUUL's marketing showed that "the growth of JUUL was accompanied  
4 by innovative marketing across a variety of new media platforms...JUUL was one of the first major  
5 retail e-cigarette brands that relied heavily on social media to market its products."<sup>9</sup> The study further  
6 found that JUUL's Instagram account reached a quarter million followers, used artsy photographs to  
7 display its products and "evoke lifestyle feelings such as relaxation, freedom and sex appeal."

8           50.     The Surgeon General's Advisory on E-Cigarette Use Among Youth found that  
9 JUUL's Twitter account was being followed by adolescents and that 25% of those retweeting official  
10 JUUL tweets were under 18.

11           51.     JUUL has also played off the ubiquity of Apple products such as iPhones and iPads.  
12 JUUL promotes itself with statements like JUUL is "the iPhone of e-cigarettes," which JUUL posted on  
13 its website and used as the basis for a social media and email campaign.  
14

15           52.     JUUL is available in sweet flavors including mango, fruit medley and cool mint.  
16 According to one survey, 81 percent of current youth e-cigarette users cited the availability of appealing  
17 flavors as the primary reason for use.<sup>10</sup>  
18

19           53.     JUUL's viral marketing campaign has been successful. The National Youth Tobacco  
20 Survey has found that 78.2 percent of middle and high-school students – 20.5 million youth – had been  
21 exposed to e-cigarette advertisements.

22           54.     JUUL has styled itself as something different than Big Tobacco. For example, JUUL  
23 had a campaign that expressly stated: "FACT: JUUL Labs is not Big Tobacco. We are an independent  
24

25  
26 <sup>9</sup> Huang, J, et al., "Vaping versus JUULing: how the extraordinary growth and marketing of JUUL  
27 transformed the US retail, available at  
<https://tobaccocontrol.bmj.com/content/tobaccocontrol/early/2018/05/31/tobaccocontrol-2018-054382.full.pdf>.

28 <sup>10</sup> Villanti AC, Johnson AL, Ambrose BK, et al. Use of flavored tobacco products among U.S. youth and adults; findings from the first wave of the PATH Study (2013-2014)

vapor company on a mission to eliminate cigarettes.” That has proved false. As discussed below, Altria acquired 35% of JUUL to partner with the company.

**D. Philip Morris, An Altria Subsidiary, Has a Long History of Marketing Tobacco Products to Youth**

55. Beginning in the 1950s through the present, Philip Morris intentionally marketed cigarettes to young people under the age of 21 to recruit “replacement smokers” to ensure the economic future of the tobacco industry. *See U.S. v. Philip Morris, et al.*, No. 99-cv-2496, Amended Final Opinion at page 972 (D.D.C. Aug. 17, 2006) (Kessler, J.).

56. Philip Morris knew that marketing cigarettes to youth is essential to the company’s success and longevity, and for that reason, it created marketing campaigns to increase youth consumption.

57. An internal memorandum dated March 31, 1981 sent by Myron Johnston, a marketing researcher for Philip Morris, states: “It is important to know as much as possible about teenage smoking patterns and attitudes. Today’s teenager is tomorrow’s potential regular customer, and the overwhelming majority of smokers first begin to smoke while still in their teens.” *See Young Smokers: Prevalence, Trends, Implications, and Related Demographic Trends*, p. 6.

58. To accomplish this sordid goal, Philip Morris tracked youth behavior and preference; employed marketing themes that resonated with youth; and promoted cigarettes to youth through retail promotions, events and sponsorships. *See U.S. v. Philip Morris, et al.*, at pages 1006, 1072.

59. Philip Morris intentionally exploited adolescents’ vulnerability to imagery by creating advertising that utilizes the themes of independence, adventurousness, sophistication, glamour, athleticism, social inclusion, sexual attractiveness, thinness, popularity, rebelliousness, and being “cool.” Philip Morris’ marketing tactics consistently reached millions of teens. *Id.* at page 990

60. Philip Morris’ youth brand is Marlboro, which was and remains among the most heavily advertised brands. *Id.*, at pages 980, 991.

1           61. Philip Morris was adjudged to have engaged in unlawful coordinated activity to  
2 "recruit new, youth smokers through cigarette marketing," and falsely denied that it marketed to  
3 youth.

4           62. The Racketeering Acts associated with Philip Morris' youth marketing consisted of  
5 advertisements that appeal to and target youth, the designs of which are based on its research on  
6 teenage behaviors and preferences. *Id.*, at page 1519.

7           63. The Altria Defendants have not abandoned their youth-appealing themes. Up until it  
8 acquired a 35% stake in JUUL, described below, Altria Defendants had their own e-cigarette, the  
9 MarkTen products, which Altria conceded was popular among youth.

11           **E. The Government Takes Action to Address the E-Cigarette Epidemic**

12           64. On February 24, 2018, the FDA sent a letter to JUUL expressing concern about the  
13 popularity of JUUL products among youth. The FDA ordered JUUL to submit documents regarding its  
14 marketing practices. The FDA publicized this letter on its website.

15           65. On September 12, 2018, the FDA sent letters to five e-cigarette manufacturers that  
16 represent more than 97 percent of the current market. JUUL and Altria were among these  
17 manufacturers. The FDA commissioner, Dr. Gottlieb, stated these companies are "now on notice by  
18 the FDA of how their products are being used by youth at disturbing rates." Further, the FDA  
19 requested "the manufacturers of these brands and products to come back to the FDA in 60 days with  
20 robust plans on how they'll convincingly address the widespread use of their products by minors."  
21 Dr. Gottlieb ordered the companies to "demonstrate that they're truly committed to keeping these [e-  
22 cigarettes] out of the hands of kids and they must find a way to reverse this trend."  
23

24           66. On October 4, 2018, JUUL stated it released 50,000 pages of documents to the FDA  
25 and that it "want[s] to be part of the solution in preventing underage use."  
26  
27  
28



1           67.     On October 18, 2018, Altria's CEO met with members of the FDA leadership. During  
2 that meeting, Altria acknowledged it had an obligation to address the epidemic of youth use of e-  
3 cigarettes.

4           68.     Publicly, and in response to the FDA's alarm concerning the rise in youth e-cigarette  
5 use, Altria's CEO, Howard Willard, stated, in letter to the FDA of October 25, 2018, that the company  
6 is "alarmed about the reported rise in youth e-vapor use to epidemic levels." Mr. Willard further wrote  
7 that Altria believed that pod-based products significantly contributed to the rise in youth use of e-vapor  
8 products and committed to "remove from the market our *MarkTen Elite* and *Apex by MarkTen* pod-  
9 based products until we receive a market order from FDA or the youth issue is otherwise addressed."  
10 Mr. Willard also wrote: "We are committed to helping reverse the current [vaping] use and trend among  
11 youth."  
12

13           69.     On November 14, 2018, JUUL announced a plan to combat underage use.

14           70.     A day later, on November 15, the CDC announced that e-cigarette use in general  
15 increased 78 percent among high school students and 48 percent among middle school students from  
16 2017 to 2018. The FDA Commissioner called these results "astonishing."  
17

18           71.     On December 7, 2018, Altria announced it would discontinue production and  
19 distribution of all MarkTen products and said it will "refocus its resources on more compelling reduced-  
20 risk tobacco product opportunities."  
21

22           72.     On December 18, 2018, the Secretary of the U.S. Department of Health and Human  
23 Services, Alex Azar, stated at a press conference: "We have never seen use of any substance by  
24 America's young people rise as rapidly as e-cigarette use is rising."

25           **F. Altria Defendants Long-Monitored JUUL's Growth And Recently Purchased a**  
26           **Controlling Stake to Partner With JUUL**

27           73.     Altria's public stance on e-cigarettes markedly differed from its private undertakings  
28 with respect to JUUL.

1           74.     The Altria Defendants closely and carefully monitored the details of JUUL's business  
2 for years prior to its decision to buy into JUUL in December 2018. In an earnings call of December  
3 2018, Altria Defendants stated that they had been in talks with JUUL's managers for "quite some time."  
4 Altria's chief executive, Howard Willard, stated: "we've been monitoring [JUUL's] growth...for three  
5 years" – in other words, since JUUL launched back in 2015.

6           75.     Altria's disclosures to the Securities and Exchange Commission reveal it had been  
7 "closely" following JUUL's journey to "see if it had staying power."  
8

9           76.     Weeks after Altria announced it would remove its e-vapor products from the market to  
10 address the youth vaping epidemic, on December 20, 2018, Altria made public that it closed a \$12.8  
11 billion investment with JUUL, the leader in e-cigarettes, amounting to a 35% stake. Thus, Altria is  
12 continuing to sell flavored e-cigarettes, which it told the FDA it would stop.

13           77.     Altria agreed to a non-competition obligation with JUUL as long as Altria is providing  
14 services to JUUL, which Altria has committed to doing for at least six years.

15           78.     Altria and JUUL also entered into a services agreement. Among other things, Altria  
16 will provide services to JUUL with respect to logistics and distribution, access to retail shelf space,  
17 youth vaping prevention, cigarette pack inserts and onserts, regulatory matters and government  
18 affairs. Altria has also agreed to grant JUUL a non-exclusive, royalty-free perpetual, irrevocable,  
19 sublicensable license to Altria's non-trademark licensable intellectual property rights in the e-vapor  
20 field, subject to the terms and conditions set forth in an intellectual property license agreement  
21 between the parties.  
22

23           79.     Pursuant to the agreement Altria has agreed to provide JUUL with certain commercial  
24 services on a cost-plus-3% basis for an initial term of six years.  
25

26           80.     Pursuant to the agreement Altria will provide JUUL access to its prime retail shelf  
27 space, which will allow JUUL products to appear alongside Philip Morris combustible cigarettes like  
28 Marlboro, the country's most popular cigarette brand. Altria will also provide JUUL, through the

1 Altria Group Distribution Company, sales and distribution services and thus: access to Altria's near  
2 230,000 retail locations.

3 81. Pursuant to the agreement, Philip Morris, which maintains a database of cigarette  
4 smokers' mailing and email addresses, will send JUUL advertising and marketing messages to its  
5 customers.

6 82. Further, pursuant to the agreement JUUL will benefit from Altria's influence with  
7 legislators and regulators and the expertise of Altria's legal team in countering tobacco litigation.  
8

9 83. At a conference call on December 20, 2018, Altria's CEO remarked that Altria felt  
10 "fortunate to be the tobacco company that's partnered up with JUUL" and that Altria would provide  
11 its infrastructure to JUUL in order to accelerate JUUL's growth. During that call, Altria said it would  
12 continue to market conventional cigarettes "vigorously."

13 84. According to Robert K. Jackler, MD, Principal Investigator of the Stanford Research  
14 into the Impact of Tobacco Advertising: "The joining of JUUL and Marlboro brings together the two  
15 dominant players in the teenage nicotine addiction market (e-cigarette & cigarette). This powerful  
16 combination constitutes a clear and present danger to the youth of America as well as those around  
17 the world."  
18

19 85. Studies demonstrate that e-cigarette use is associated with increased risk for cigarette  
20 initiation and use, particularly among low-risk youths. See Berry KM, Fetterman JL, Benjamin EJ, et  
21 al. Association of Electronic Cigarette Use With Subsequent Initiation of Tobacco Cigarettes in US  
22 Youths. *JAMA Netw Open*. 2019;2(2):e187794. doi:10.1001/jamanetworkopen.2018.7794.  
23

24 86. Recent promotional practices of both companies suggest that they may pursue a  
25 strategy by which youth start with JUUL and graduate to Marlboro:  
26  
27  
28

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13



MARLBORO MENTHOL  
**SWITCH IT UP**  
RESEAL  
REPEAT  
WIN


**1000s OF CUTTING-EDGE PRIZES.  
ALL PACKED IN THE NEW RESEAL PACK.**

AND ONLY ONE WAY TO REVEAL WHAT'S NEXT.

ENTER FOR YOUR CHANCE TO  
WIN INSTANTLY AT  
**MARLBORO.COM**

SITE LIMITED TO ELIGIBLE SHOPS TO 13480 OF AGE OR OLDER







**JUUL®**

**FLAVOR  
MULTIPACK**  
4 Pods  
5.0% Strength

- Mint
- Virginia Tobacco
- Creme
- Mango



The Alternative For Adult Smokers









**Marlboro<sup>®</sup> 72s**  
NEVER SHORT ON FLAVOR



**NOW AVAILABLE IN BLACK MENTHOL**

DISCOVER THE FLAVORS  
AT MARLBORO.COM



See retailer for details and more. 21 years of age or older.




Original JUUL Design

Recent JUUL Design

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28



**Leading Youth Cigarette Initiation Brand**



**Leading Youth e-Cigarette Initiation Brand**

**FIRST CAUSE OF ACTION**

## Civil Conspiracy

87. Plaintiff incorporates by reference paragraphs 1-86 above as if fully set forth herein, and further declare:

88. Defendants JUUL, Altria, Philip Morris, Adam Bowen, and James Monsees are all “persons” for purposes of this cause of action.

89. Defendants JUUL, Altria, Philip Morris, Adam Bowen, and James Monsees have been conspiring, to sell and promote JUUL and have engaged in unlawful marketing practices to do so.

90. Since at least as long as Defendants JUUL, Altria and Philip Morris, have entered into an agreement with respect to JUUL e-cigarettes, and continuing up to and including the date of the filing of this complaint, Defendants have been functioning to achieve shared goals through unlawful means including to deceive consumers, particularly parents and children, by claiming that they did not market to children, while engaging in marketing and advertising with the intent of addicting children into becoming lifetime nicotine users.

91. As detailed in the General Factual Allegations, these Defendants' know that marketing JUUL e-cigarettes to youth is essential to Defendants' success and longevity, and for that reason, they partnered to create marketing campaigns to increase youth consumption, while fraudulently denying they are doing so. Defendants have furthered this scheme to profit. Defendants' collaboration, as evidenced by a services agreement, marketing campaign, fraudulent statements, and misrepresentations constitute overt acts in pursuance on the conspiracy.

92. The Defendants' conduct in furtherance of this scheme was intentional. Plaintiff was directly harmed as a result of the Defendants' intentional conduct.



93. Defendants have directly and proximately caused injuries and damages to Plaintiff. Equitable relief is necessary to ensure an end to Defendants' continued effort to deceptively campaign to induce children and minors to become addicted and subject to a high risk of disease.

## SECOND CAUSE OF ACTION

## Fraud

94. Plaintiff incorporates by reference paragraphs 1-86 above as if fully set forth herein and further declare:

95. At all times relevant, Defendants fraudulently and deceptively sold or partnered to sell JUUL products to Plaintiff as non-addictive nicotine delivery systems, or less addictive nicotine products than cigarettes, when Defendants knew it to be untrue.

96. Defendants also fraudulently and deceptively failed to disclose to Plaintiff that the JUUL nicotine salts he purchased were highly addictive in nature, making it extremely difficult for Plaintiff to cease purchasing JUULpod refills.

97. Defendants further fraudulently and deceptively failed to disclose to Plaintiff that JUUL is designed to create and sustain an addiction to nicotine. Defendants also manipulated the formulations of JUUL devices and JUULpods in ways that could and would impact their potency and addictiveness, and Defendant did so without notifying Plaintiff. Defendants actively concealed the nicotine content and nicotine potency of JUUL e-cigarettes.

98. Each of these misrepresentations and omissions were material at the time they were made. In particular, each of the misrepresentations and omissions concerned material facts that were essential to the analysis undertaken by Plaintiff, as to whether to purchase a JUUL E-cigarette and JUULpod.

99. Defendants had a duty to accurately provide this information to Plaintiff. In not informing Plaintiff, Defendants breached their duties. Defendants also gained financially from, and as a result of, their breach.

100. Defendants concealed material information at all times relevant to this Complaint. Defendants have yet to disclose the truth about JUUL e-cigarettes.

101. Plaintiff relied to his detriment on Defendants' fraudulent omissions. Had Plaintiff been adequately informed and not intentionally deceived by Defendant, he would not have purchased or used JUUL products.

102. Plaintiff harmed directly and proximately by Defendants' fraud. Such harm includes personal injury, significant exposure to toxic substances, which may cause or contribute to causing personal injury; disease; nicotine addiction; and economic harm, in that he would not have purchased JUUL or would have paid less for it if he had known the true facts and that he had paid a premium as a result of Defendants' fraud.

103. Defendants' conduct as described herein was willful and malicious and was designed to maximize Defendants' profits even though Defendant knew that it would cause loss and harm to Plaintiff.

### THIRD CAUSE OF ACTION

### **Strict Product Liability – Failure to Warn**

104. Plaintiff incorporates by reference paragraphs 1-86 above as if fully set forth herein and further declare:

105. Defendants manufactured, distributed and sold and promoted JUUL, or have partnered to manufacture, distribute, sell and promote JUUL.

106. At all times relevant, Defendants were well-aware of the dangers of nicotine addiction as described in this complaint.

107. At all times relevant, Plaintiff was not aware of and would not have recognized the risks of using a JUUL device with a JUUL pod because Defendant JUUL has intentionally downplayed, misrepresented, concealed, and failed to warn of the heightened risks of nicotine exposure and addiction. Since the Altria Defendants partnered with JUUL, they too intentionally

1 downplayed, misrepresented, concealed, and failed to warn of the heightened risks of nicotine  
2 exposure and addiction.

3 108. In all forms of advertising as well as social media communications, Defendants failed  
4 adequately to warn or instruct foreseeable users, including youth and adolescent users, that JUUL  
5 products were unreasonably dangerous to them and created a high level of risk of harms caused by  
6 nicotine exposure and addiction as explained herein. Defendants failed adequately to warn in their  
7 advertising, social media communications, or anywhere on the product label that the product was not  
8 safe for minors and should not be used or consumed by them. Instead, as described herein, Defendants  
9 marketed their products to minors and made them available in youth-friendly colors and flavors.  
10 Defendants also designed their products to be more palatable to youth and nonsmokers by increasing  
11 JUUL's inhale-ability and increased the level of nicotine that is absorbed by users, making them even  
12 more addictive.  
13

14 109. The defects in JUUL Products, including the lack of warnings, existed at the time the  
15 JUUL pods and devices were sold and/or when the JUUL pods and devices left JUUL's possession or  
16 control.  
17

18 110. The JUUL devices and pods were expected to be used by Plaintiff without substantial  
19 change in their condition from the time of their manufacture or sale.

20 111. Plaintiff was harmed directly and proximately by Defendants' failure to warn. Such  
21 harm includes personal injury, significant exposure to toxic substances, which may cause or  
22 contribute to causing personal injury; disease; nicotine addiction; economic harm, in that he would  
23 not have purchased JUUL or would have paid less for it if he had known the true facts and that he had  
24 paid a premium as a result of Defendants' failure to warn.  
25

#### 26 **FOURTH CAUSE OF ACTION**

#### 27 **Strict Product Liability – Design Defect**

1           112. Plaintiff incorporates by reference paragraphs 1-86 above as if fully set forth herein  
2 and further declare:

3           113. Defendants JUUL, Monsees and Bowen, designed, engineered, developed,  
4 manufactured, fabricated, assembled, equipped, tested or failed to test, inspected or failed to inspect,  
5 labeled, advertised, promoted, marketed, supplied, distributed, wholesaled, and sold the JUUL  
6 devices and JUUL pods, which were intended by JUUL to be used as a method of ingesting nicotine  
7 and the other aerosolized constituents of JUUL's nicotine solution. Since the Altria Defendants  
8 partnered with JUUL, they have assisted with one or more of these activities.  
9

10           114. Defendants knew or, by the exercise of reasonable care, should have known that  
11 JUUL's products under ordinary use were harmful or injurious, particularly to youths and  
12 adolescents, including the Plaintiff.

13           115. As described in this complaint, Defendants designed and marketed their products to  
14 appeal to nonsmokers, youths and adolescents and to encourage them to buy and use the product.  
15

16           116. JUUL products are also inherently defective because they contain and deliver  
17 significantly more nicotine than JUUL represents. Moreover, JUUL is unreasonably dangerous and  
18 therefore defective in design because it is made to create and sustain addiction. The risks inherent in  
19 the design of JUUL outweigh significantly any benefits of such design.

20           117. At all relevant times, Defendants could have employed reasonably feasible alternative  
21 designs to prevent the harms discussed in the complaint.  
22

23           118. At all relevant times, Plaintiff was unaware of the design defects described in the  
24 complaint. Further, Defendants knew or had reason to know that youths and adolescents would not  
25 fully realize the dangerous and addictive nature of the JUUL products and the long-term  
26 complications nicotine addiction can present, or that, due to their youth, inexperience and/or  
27 immaturity of judgment, would recklessly disregard such risks.  
28

1           119. Plaintiff was harmed directly and proximately by Defendants' defectively designed  
2 JUUL e-cigarette. Such harm includes personal injury, significant exposure to toxic substances,  
3 which may cause or contribute to causing personal injury; disease; nicotine addiction; economic  
4 harm; in that he would not have purchased JUUL or would have paid less for it if he had known the  
5 true facts and that he had paid a premium as a result of Defendants' defective products.

6                                   **FIFTH CAUSE OF ACTION**

7                                   **Negligence**

8  
9           120. Plaintiff incorporates by reference paragraphs 1-86 above as if fully set forth herein  
10 and further declare:

11           121. Defendants had a duty and owed a duty to Plaintiff to exercise a degree of reasonable  
12 care including, but not limited to: ensuring that JUUL marketing does not target minors; ensuring that  
13 JUUL devices and JUULpods are not sold and/or distributed to minors and are not designed in a  
14 manner that makes them unduly attractive to minors; designing a product that is not defective and  
15 unreasonably dangerous; designing a product that will not addict youth or other users to nicotine;  
16 adequately warning of any reasonably foreseeable adverse events with respect to using the product.

17  
18           122. Defendants knew the risks that minors would be attracted to their electronic cigarette  
19 devices and JUULpods and knew or should have known the importance of ensuring that the products  
20 were not sold and/or distributed to minors.

21           123. Defendants knew or should have known that their marketing, distribution, and sales  
22 practices did not adequately safeguard Plaintiff from the sale and/or distribution of electronic  
23 cigarette devices and JUULpods and, in fact, induced minors to purchase JUUL products.

24  
25           124. Defendants breached the duties they owed to Plaintiff.

26           125. But for Defendants' duties and breaches thereof, Plaintiff would not have been harmed  
27 as alleged in the Complaint.  
28

1           126. Plaintiff was harmed directly and proximately by Defendants' negligence. Such harm  
2 includes personal injury, significant exposure to toxic substances, which may cause or contribute to  
3 causing personal injury; disease; nicotine addiction; and economic harm; in that he would not have  
4 purchased JUUL or would have paid less for it if he had known the true facts and that he had paid a  
5 premium because of Defendants' negligence.

6                                   **SIXTH CAUSE OF ACTION**

7                                   **Unjust Enrichment**

8  
9           127. Plaintiff incorporates by reference paragraphs 1-86 above as if fully set forth herein  
10 and further declare:

11           128. As described in the complaint, Defendants knowingly sold or partnered to sell JUUL  
12 Products to Plaintiff in a manner that was unfair, unconscionable, and oppressive.

13           129. As a result of Defendants' unlawful and deceptive actions described above,  
14 Defendants were enriched at the expense of Plaintiff.

15           130. Under the circumstances, it would be against equity and good conscience to permit  
16 Defendants to retain the ill-gotten benefits it received from Plaintiff. Thus, it would be unjust and  
17 inequitable for Defendants to retain the benefit without restitution to Plaintiff for the monies paid to  
18 Defendants for its defective JUUL products.

19                                   **SEVENTH CAUSE OF ACTION**

20                                   **Violation of California's Unfair Competition Law ("UCL")**  
21                                   **CAL. BUS. & PROF. CODE § 17200**

22           131. Plaintiff incorporates by reference paragraphs 1-86 above as if fully set forth herein  
23 and further declare:

24           132. The UCL makes unlawful "unfair or fraudulent business act or practice." CAL. BUS. &  
25 PROF. CODE § 17200 (WEST 2019).

26           133. Defendants are "persons[s]" as defined by UCL§ 17201.

1           134. Defendants' unfair and deceptive practices are likely to mislead – and have misled –  
2 reasonable consumers, such as Plaintiff, and therefore, violate UCL § 17200.

3           135. Defendants have engaged and continue to engage in unfair, unlawful, and deceptive  
4 trade practices in California as outlined herein. In particular, Defendants have knowingly developed,  
5 sold, and promote a product that contained nicotine levels in excess of cigarettes with the intention of  
6 creating and fostering long-term addiction to JUUL products for minors to continue that addiction  
7 into adulthood; selling a product that aggravates nicotine addiction; creating advertising to target  
8 youth into using JUUL e-cigarettes, and disseminating that advertising through unregulated social  
9 media platforms commonly used by youth. Plaintiff reasonably relied to his detriment on Defendants'  
10 unlawful conduct in that he purchased JUUL not knowing the true propensity of its dangers.

11           136. Plaintiff sustained damages as a direct and proximate result of Defendants' tortious  
12 conduct.  
13

14           137. Plaintiff seeks injunctive relief to prohibit Defendants from continuing to engage in  
15 the unfair and deceptive advertising and marketing practices complained of in this complaint. Such  
16 misconduct by Defendants, unless and until enjoined and restrained by order of this Court, will  
17 continue to cause injury in fact.  
18

19  
20                                   **EIGHTH CAUSE OF ACTION**

21                           **Violation of California's Consumers Legal Remedies Act ("CLRA")**  
22                                   **CAL. CIV. CODE § 1770**

23           138. Plaintiff incorporates by reference paragraphs 1-86 above as if fully set forth herein  
24 and further declare:

25           139. The CLRA makes unlawful "unfair methods of competition and unfair or deceptive  
26 acts or practice undertaken by any person in a transaction intended to result or that results in the sale  
27 of lease of goods or services to any consumer." CAL. CIV. CODE § 1770 (WEST 2019).  
28

140. Manufacturing, selling, promoting e-cigarettes in interstate commerce are “transaction” and “services” in the scope of CLRA, and JUUL is a “good” within the meaning of CLRA § 1761. CAL. CIV. CODE § 1761 (WEST 2019).

141. Plaintiff is a “consumer” as defined by CLRA § 1761. CAL. CIV. CODE § 1761(d) (WEST 2019).

142. Defendants are “persons[s]” as defined by CLRA § 1761. CAL. CIV. CODE § 1761(c) (WEST 2019).

143. Defendants' unfair and deceptive practices are likely to mislead – and have misled – reasonable consumers, such as Plaintiff, and therefore, violate CLRA § 1770.

144. Defendants have engaged and continue to engage in unfair, unlawful, and deceptive trade practices in California as outlined herein. In particular, Defendants have knowingly developed, sold, and promote a product that contained nicotine levels in excess of cigarettes with the intention of creating and fostering long-term addiction to JUUL products for minors to continue that addiction into adulthood; selling a product that aggravates nicotine addiction; creating advertising to target youth into using JUUL e-cigarettes, and disseminating that advertising through unregulated social media platforms commonly used by youth. Plaintiff reasonably relied to his detriment on Defendants' unlawful conduct in that he purchased JUUL not knowing the true propensity of its dangers.

145. Plaintiff sustained damages as a direct and proximate result of Defendants' tortious conduct.

146. Plaintiff seeks injunctive relief to prohibit Defendants from continuing to engage in the unfair and deceptive advertising and marketing practices complained of in this complaint. Such misconduct by Defendants, unless and until enjoined and restrained by order of this Court, will continue to cause injury in fact.

147. Pursuant to the CLRA § 1780, Plaintiff makes claims for actual damages, punitive damages, and any other relief that the court deems proper. The damages suffered by the Plaintiff was



1 directly and proximately caused by the deceptive, misleading and unfair practices of Defendants.  
2 CAL. CIV. CODE § 1780 (WEST 2019).

3 **NINTH CAUSE OF ACTION**

4 **Preliminary and Permanent Injunction**

5  
6 148. Plaintiff incorporates by reference paragraphs 1-86 above as if fully set forth herein  
7 and further declare:

8 149. Defendants' actions – designing, marketing, and selling JUUL in ways that it knows  
9 will attract minors and deceptively downplaying the potency and danger of the nicotine in JUUL –  
10 constitute unlawful acts under California Law.

11 150. Nicotine addiction constitutes irreparable harm. Nicotine is a neurotoxin, which  
12 means that it is poisonous to the human brain. Further, the brains of teenagers are particularly  
13 vulnerable to nicotine's neurotoxic effects. Nicotine causes macromolecular alterations of the brain.

14 151. Based on the factual allegations above, Plaintiff established a clear legal right, an  
15 inadequate remedy at law and that irreparable harm will arise absent injunctive relief.

16 152. Thus, Defendants, officers, directors, employees, agents, and all those acting in  
17 concert with them, should be preliminarily and permanently enjoined from:

18  
19 a. Offering, selling, delivering, or in any manner, providing or facilitating others to  
20 provide JUUL products to minors within this State;

21  
22 b. Offering, selling, delivering, or in any manner, providing or facilitating others to  
23 provide any flavors other than tobacco through online sales;

24 c. Engaging or participating in any marketing or advertising activities within this State  
25 that are intended or are known to likely appeal to minors, and should thus be enjoined from: sending  
26 marketing emails to minors within this State; advertising outdoors within 1,000 feet of schools and  
27 playgrounds within this State; sponsor any sporting, entertainment, or charity event in this State;  
28

1 providing free or discounted samples, starter kits or e-cigarette products to consumers, including  
2 being enjoyed from providing automatic renewals or bulk orders; advertising in any fashion in media  
3 or outlets that serve consumers under 30 years;

4 d. Offering, selling, delivering, or in any manner, providing or facilitating others to  
5 provide JUUL products within this State unless and until JUUL obtains Premarket Approval or  
6 approved as a Modified Risk Tobacco Product under the Tobacco Control Act.

7  
8  
9 **PRAYER FOR RELIEF**

10 WHEREFORE, Plaintiff prays for judgment as follows:


- 11 A. An order enjoining Defendants from further negligent, deceptive, unfair, and unlawful  
12 conduct as alleged herein;  
13 B. Awarding actual, compensatory, and consequential damages;  
14 C. Awarding other monetary and equitable relief for diagnostic testing, medical monitoring,  
15 and nicotine cessation programs;  
16 D. Awarding restitution;  
17 E. Awarding reasonable attorneys' fees, and costs of this case;  
18 F. Awarding prejudgment and post-judgment interest;  
19 G. Such other and further relief as the Court deems appropriate under the circumstances.  
20

21 **JURY TRIAL DEMAND**

22 Plaintiff hereby demands a jury trial on all issues so triable.  
23

24 Dated: July 23, 2019

Respectfully submitted,

25  
26 

27 Martin Schmidt, Esq.  
28 SCHMIDT NATIONAL LAW GROUP  
9191 Towne Centre Drive, Suite 510  
San Diego, California 92122

AND

\_\_\_\_\_  
Scott P. Schlesinger (*pro hac vice anticipated*)  
Jonathan R. Gonski (*pro hac vice anticipated*)  
Jeffrey L. Haberman (*pro hac vice anticipated*)  
SCHLESINGER LAW OFFICES, P.A.  
1212 SE Third Avenue  
Ft. Lauderdale, FL 3316